Trade facing article
This is written for clinic owners and staff. The patient facing versions of the same material are in before and after photographs and social media promotion. As everywhere on this site, we name no businesses.
Compliance in this sector is not one rule book. It is four, applying simultaneously to the same piece of content, and enforced by four different bodies with different powers. Setting them out together is the fastest way to see the perimeter.
One: the CAP Code and the ASA
The UK Code of Non broadcast Advertising and Direct and Promotional Marketing applies to marketing communications including websites, social media, paid advertising, email and printed material. The core requirements relevant here:
- Marketing must not materially mislead or be likely to do so.
- Objective claims must be supported by adequate evidence held before publication.
- Marketing must not exaggerate the effect a treatment can achieve, and must not present atypical results as typical.
- Marketing communications must be obviously identifiable as such, which reaches advertorial, influencer content and affiliate arrangements.
- Marketing must be prepared with a sense of responsibility and must not exploit insecurities, particularly in relation to body image.
- Specific restrictions apply to marketing cosmetic interventions to under 18s.
The ASA can require material to be withdrawn or amended and publishes rulings naming the advertiser. Those rulings are indexed and durable.
Two: medicines advertising law
The Human Medicines Regulations 2012 prohibit advertising prescription only medicines to the general public. Botulinum toxin products are prescription only medicines.
In practice this means promotional material should not name the brand, tag the manufacturer, show the packaging or use the brand as a hashtag. Generic descriptions of the treatment are the compliant route. This applies to the clinic's own channels, to paid advertising, and to content produced by third parties under a commercial arrangement.
It is the most frequently breached rule in the sector and the easiest to audit, because it does not require a judgement call. Search your own channels for the brand names and see what comes back.
What patients are entitled to from your marketing
- Marketing that does not mislead, and objective claims supported by evidence held in advance.
- Results imagery that is comparable and not exaggerated, with atypical results not presented as typical.
- Advertising that is obviously identifiable as advertising.
- No advertising of prescription only medicines to the public.
- Freedom from manufactured urgency and from falsely claimed accreditation.
Meeting these is also the fastest way to be visibly different from most of the category.
Three: consumer protection law
The Consumer Protection from Unfair Trading Regulations 2008 prohibit misleading actions, misleading omissions and aggressive commercial practices, and list a number of practices banned outright. Several are directly relevant: falsely stating that a product will only be available for a very limited time in order to elicit an immediate decision; falsely claiming accreditation or approval; and falsely representing oneself as a consumer.
Enforcement sits with Trading Standards, and unlike the ASA route it carries the possibility of criminal liability. Pricing practices, including reference pricing and was and now claims, also fall within this regime.
Four: professional standards
If a registered clinician is involved in the business, their regulator's standards apply to them personally, regardless of who produced the marketing. GMC guidance for doctors offering cosmetic interventions addresses promotion, inducements, time limited offers, testimonials and the use of imagery. Comparable expectations exist in the standards of the GDC, NMC and GPhC.
The practical consequence is that a single non compliant campaign can produce an ASA ruling against the business and a fitness to practise concern against the named clinician. Those are separate processes with separate consequences, and only one of them ends when the advertisement is withdrawn.
Campaign approval that runs marketing, legal and clinical in parallel rather than in sequence. In this sector the clinical sign off has to be the last gate, because the person whose registration is exposed is the only one who can accept that exposure.
A practical compliance routine
Audit for brand names. Search every channel for prescription only medicine brand names, including in image alt text, file names and hashtags.
Standardise photography. Same position, distance, lighting, background and expression. No filters. Record and publish the interval and the number of sessions. Keep the raw files.
Document evidence for claims. Before publication, not after a complaint. If a claim cannot be supported by something you can produce on request, do not publish it.
Label commercial content. Prominently and up front, on every arrangement involving payment or gifted treatment.
Remove artificial urgency. Genuine promotions with real end dates are permissible. Manufactured scarcity is a banned practice.
Separate consents. Marketing consent for images is distinct from treatment consent, must specify where images will be used and for how long, and must be withdrawable.
Why this is worth doing beyond the risk
Compliant marketing in this sector is a differentiator, because so much of the category is not compliant. Named practitioners with checkable registrations, real prices, standardised photography with stated intervals, a published complications policy: all of these are compliance requirements and all of them are also the things a careful patient is looking for and cannot find. The overlap between what the rules require and what a good patient wants is close to complete, which is unusual and worth exploiting.